Gómez-Lechón MJ - Search Results

1

Competency of different cell models to predict human hepatotoxic drugs.

Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT. Gómez-Lechón MJ, et al. Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1553-68. doi: 10.1517/17425255.2014.967680. Epub 2014 Oct 9. Expert Opin Drug Metab Toxicol. 2014. PMID: 25297626 Review.

2

Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes.

Tolosa L, Jiménez N, Pelechá M, Castell JV, Gómez-Lechón MJ, Donato MT. Tolosa L, et al. Among authors: gomez lechon mj. Arch Toxicol. 2019 Feb;93(2):519-532. doi: 10.1007/s00204-018-2349-y. Epub 2018 Nov 13. Arch Toxicol. 2019. PMID: 30426164

3

Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes.

Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ. Donato MT, et al. Drug Metab Dispos. 2004 Jul;32(7):699-706. doi: 10.1124/dmd.32.7.699. Drug Metab Dispos. 2004. PMID: 15205384

4

Transcriptional regulation and expression of CYP3A4 in hepatocytes.

Martínez-Jiménez CP, Jover R, Donato MT, Castell JV, Gómez-Lechón MJ. Martínez-Jiménez CP, et al. Curr Drug Metab. 2007 Feb;8(2):185-94. doi: 10.2174/138920007779815986. Curr Drug Metab. 2007. PMID: 17305497 Review.

5

Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.

Tolosa L, Donato MT, Pérez-Cataldo G, Castell JV, Gómez-Lechón MJ. Tolosa L, et al. Toxicol In Vitro. 2012 Dec;26(8):1272-7. doi: 10.1016/j.tiv.2011.11.008. Epub 2011 Nov 25. Toxicol In Vitro. 2012. PMID: 22138474

6

Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.

Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE, Gómez-Lechón MJ. Tolosa L, et al. Toxicol Sci. 2012 May;127(1):187-98. doi: 10.1093/toxsci/kfs083. Epub 2012 Feb 13. Toxicol Sci. 2012. PMID: 22331495

7

Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates.

Donato MT, Gómez-Lechón MJ. Donato MT, et al. Curr Drug Metab. 2012 Oct;13(8):1160-73. doi: 10.2174/138920012802850001. Curr Drug Metab. 2012. PMID: 22746303 Review.

8

HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.

Tolosa L, Gómez-Lechón MJ, Pérez-Cataldo G, Castell JV, Donato MT. Tolosa L, et al. Arch Toxicol. 2013 Jun;87(6):1115-27. doi: 10.1007/s00204-013-1012-x. Epub 2013 Feb 9. Arch Toxicol. 2013. PMID: 23397584

9

Neonatal livers: a source for the isolation of good-performing hepatocytes for cell transplantation.

Tolosa L, Pareja-Ibars E, Donato MT, Cortés M, López S, Jiménez N, Mir J, Castell JV, Gómez-Lechón MJ. Tolosa L, et al. Cell Transplant. 2014;23(10):1229-42. doi: 10.3727/096368913X669743. Epub 2013 Jun 25. Cell Transplant. 2014. PMID: 23803290 Free article.

10

Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering.

Donato MT, Jover R, Gómez-Lechón MJ. Donato MT, et al. Curr Drug Metab. 2013 Nov;14(9):946-68. doi: 10.2174/1389200211314090002. Curr Drug Metab. 2013. PMID: 24160292 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

242 results

Search Page

Filters